FI891020A - Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi - Google Patents

Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi Download PDF

Info

Publication number
FI891020A
FI891020A FI891020A FI891020A FI891020A FI 891020 A FI891020 A FI 891020A FI 891020 A FI891020 A FI 891020A FI 891020 A FI891020 A FI 891020A FI 891020 A FI891020 A FI 891020A
Authority
FI
Finland
Prior art keywords
preparing
protease inhibitor
inhibitor activity
mutants
amino acids
Prior art date
Application number
FI891020A
Other languages
English (en)
Swedish (sv)
Other versions
FI891020A0 (fi
FI96116B (fi
FI96116C (fi
Inventor
Markus Gerhard Gruetter
Dirk Heinz
Manfred Liersch
Original Assignee
Ciba Geigy Ag
Ucp Gen Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Ucp Gen Pharma Ag filed Critical Ciba Geigy Ag
Publication of FI891020A0 publication Critical patent/FI891020A0/fi
Publication of FI891020A publication Critical patent/FI891020A/fi
Publication of FI96116B publication Critical patent/FI96116B/fi
Application granted granted Critical
Publication of FI96116C publication Critical patent/FI96116C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pest Control & Pesticides (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
FI891020A 1988-03-07 1989-03-03 Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi FI96116C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07
CH84088 1988-03-07

Publications (4)

Publication Number Publication Date
FI891020A0 FI891020A0 (fi) 1989-03-03
FI891020A true FI891020A (fi) 1989-09-08
FI96116B FI96116B (fi) 1996-01-31
FI96116C FI96116C (fi) 1996-05-10

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891020A FI96116C (fi) 1988-03-07 1989-03-03 Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi

Country Status (20)

Country Link
US (1) US5079229A (fi)
EP (1) EP0332576B1 (fi)
JP (1) JP2716191B2 (fi)
KR (1) KR0134377B1 (fi)
AT (1) ATE103930T1 (fi)
AU (1) AU623881B2 (fi)
CA (1) CA1339105C (fi)
DD (1) DD283645A5 (fi)
DE (1) DE58907373D1 (fi)
DK (1) DK107389A (fi)
ES (1) ES2063161T3 (fi)
FI (1) FI96116C (fi)
HU (1) HU209401B (fi)
IE (1) IE62993B1 (fi)
IL (1) IL89496A0 (fi)
NO (1) NO178870C (fi)
NZ (1) NZ228208A (fi)
PT (1) PT89916B (fi)
TW (1) TW211522B (fi)
ZA (1) ZA891679B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
WO1998013387A1 (en) 1996-09-24 1998-04-02 The Procter & Gamble Company Stabilized proteinaceous protease inhibitors and variants thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
CA1297437C (en) * 1983-11-21 1992-03-17 Hans Rink Process for the preparation of protease inhibitors
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
EP0164719B1 (en) * 1984-06-14 1992-05-06 Chiron Corporation Active site modified protease alpha-1-antitrypsin inhibitors and their production
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
HUT50503A (en) 1990-02-28
IL89496A0 (en) 1989-09-10
PT89916B (pt) 1994-05-31
KR890014735A (ko) 1989-10-25
DD283645A5 (de) 1990-10-17
NO890932D0 (no) 1989-03-06
FI891020A0 (fi) 1989-03-03
US5079229A (en) 1992-01-07
NO890932L (no) 1989-09-08
NZ228208A (en) 1990-08-28
FI96116B (fi) 1996-01-31
NO178870C (no) 1996-06-19
KR0134377B1 (ko) 1998-04-20
FI96116C (fi) 1996-05-10
ES2063161T3 (es) 1995-01-01
IE62993B1 (en) 1995-03-08
EP0332576A3 (en) 1990-09-12
ATE103930T1 (de) 1994-04-15
CA1339105C (en) 1997-07-29
ZA891679B (en) 1989-10-25
EP0332576B1 (de) 1994-04-06
AU3095989A (en) 1989-09-07
PT89916A (pt) 1989-11-10
DK107389A (da) 1989-09-08
DE58907373D1 (de) 1994-05-11
AU623881B2 (en) 1992-05-28
HU209401B (en) 1994-05-30
JPH029392A (ja) 1990-01-12
TW211522B (fi) 1993-08-21
IE890719L (en) 1989-09-07
DK107389D0 (da) 1989-03-06
NO178870B (no) 1996-03-11
JP2716191B2 (ja) 1998-02-18
EP0332576A2 (de) 1989-09-13

Similar Documents

Publication Publication Date Title
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
UA27035C2 (uk) Кристал білка, зшитого багатофуhкціоhальhим зшивальним агеhтом (варіаhти), пристрій, що містить кристал білка та спосіб отримаhhя аспартаму
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
FI891020A (fi) Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi
DE68917837D1 (de) Peptid-Verbindungen.
MY103362A (en) Production of proteins in active forms
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
IT1230689B (it) Metodo per realizzare mobili, particolarmente poltrone, divani o simili, da fogli di feltro trattati con sostanze indurenti e mobili relativi
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
FI961584A (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
HUT44609A (en) Process for preparing new polypeptides
AU637589B2 (en) Ancrod proteins, their production and use
Tasaka et al. Enzymatic Studies on the Egg white Proteins On the Variation of pH and Denaturation of Protein during the Course of storage (Part 2)
IT8223609A0 (it) Procedimento per l'estrazione di sostanze azotate, in particolare proteine e/o amminoacidi da sostanze vegetali, in particolare da sottoprodotti della lavorazione della soia.
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
BG48749A1 (en) Method for simultaneous obtaining of protein inhibitors

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: NOVARTIS AG

MM Patent lapsed

Owner name: NOVARTIS AG

Owner name: UCP GEN-PHARMA AG